"Off-Label Use" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The practice of prescribing or using a drug outside the scope of the drug's official approved label as designated by a regulatory agency concerning the treatment of a particular disease or condition.
Concept/Terms
Off-Label Use- Off-Label Use
- Off Label Use
- Off-Label Uses
- Use, Off-Label
- Uses, Off-Label
- Unlabeled Indication
- Indication, Unlabeled
- Indications, Unlabeled
- Unlabeled Indications
- Off-Label Prescribing
- Off Label Prescribing
- Off-Label Prescribings
- Prescribing, Off-Label
- Prescribings, Off-Label
Below are MeSH descriptors whose meaning is more general than "Off-Label Use".
Below are MeSH descriptors whose meaning is more specific than "Off-Label Use".
This graph shows the total number of publications written about "Off-Label Use" by people in Harvard Catalyst Profiles by year, and whether "Off-Label Use" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2008 | 1 | 0 | 1 |
2009 | 2 | 0 | 2 |
2010 | 3 | 3 | 6 |
2011 | 5 | 4 | 9 |
2012 | 7 | 3 | 10 |
2013 | 6 | 2 | 8 |
2014 | 6 | 3 | 9 |
2015 | 0 | 6 | 6 |
2016 | 5 | 3 | 8 |
2017 | 5 | 6 | 11 |
2018 | 3 | 4 | 7 |
2019 | 5 | 1 | 6 |
2020 | 5 | 10 | 15 |
2021 | 3 | 7 | 10 |
2022 | 2 | 5 | 7 |
2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Off-Label Use" by people in Profiles.
-
Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014. Jt Comm J Qual Patient Saf. 2023 09; 49(9):458-466.
-
An Off-Label Use of a Tensioned Proximal Humerus Plate for Tibiotalar Fusion: A Case Report. JBJS Case Connect. 2022 10 01; 12(4).
-
ALSUntangled #67: rituximab. Amyotroph Lateral Scler Frontotemporal Degener. 2023 08; 24(5-6):544-547.
-
Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications. J Am Med Inform Assoc. 2022 09 12; 29(10):1668-1678.
-
In Reply: Safety and Efficacy of the Off-Label Use of Pipeline Embolization Device Based on the 2018 Food and Drug Administration-Approved Indications for Intracranial Aneurysms: A Single-Center Retrospective Cohort Study. Neurosurgery. 2022 11 01; 91(5):e136.
-
Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy. Ann Am Thorac Soc. 2022 07; 19(7):1236-1239.
-
Safety and Efficacy of the Off-Label Use of Pipeline Embolization Device Based on the 2018 Food and Drug Administration-Approved Indications for Intracranial Aneurysms: A Single-Center Retrospective Cohort Study. Neurosurgery. 2022 06 01; 90(6):700-707.
-
An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. J Allergy Clin Immunol Pract. 2022 05; 10(5):1217-1228.e3.
-
HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis. Neurol Sci. 2022 Mar; 43(3):2095-2097.
-
Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort. JCO Precis Oncol. 2022 01; 6:e2100232.